CoChat

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones

Open access
Carrà, Giovanna, Panuzzo, Cristina, Torti, Davide, Parvis, Guido, Crivellaro, Sabrina, Familiari, Ubaldo, Volante, Marco, Morena, Deborah, Lingua, Marcello Francesco, Brancaccio, Mara, Guerrasio, Angelo, Pandolfi, Pier Paolo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro · 2017 · Oncotarget
Cited by 77

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Giovanna Carrà 1 , Cristina Panuzzo 1 , Davide Torti 1,2 , Guido Parvis 2,3 , Sabrina Crivellaro 1 , Ubaldo Familiari 4 , Marco Volante 4,5 , Deborah Morena 5 , Marcello Francesco Lingua 5 , Mara Brancaccio 6 , Angelo Guerrasio 1 , Pier Paolo Pandolfi 7 , Giuseppe Saglio 1,2,3 , Riccardo Taulli 5 and Alessandro Morotti 1 1 Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy 2 Division of Internal Medicine - Hematology, San Luigi Gonzaga Hospital, Orbassano, Italy 3 Division of Hematology, Azienda Ospedaliera, Mauriziano, Torino, Italy 4 Division of Pathology, San Luigi Hospital, Orbassano, Italy 5 Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy 6 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 7 Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Correspondence to: Alessandro Morotti, email: // Riccardo Taulli, email: // Keywords : chronic lymphocytic leukemia, USP7, PTEN, miR181, miR338 Received : June 14, 2016 Accepted : February 20, 2017 Published : March 17, 2017 Abstract Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-expressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53- wild type and -null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.16348

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 77

Metadata

Authors
Carrà, G., Panuzzo, C., Torti, D., Parvis, G., Crivellaro, S., Familiari, U., Volante, M., Morena, D., Lingua, M. F., Brancaccio, M., Guerrasio, A., Pandolfi, P. P., Saglio, G., Taulli, R., & Morotti, A.
Venue
Oncotarget
Published
2017-03-17
Volume
8
Issue
22
Pages
35508-35522
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2597394530
Cited by
77
References
7
FWCI
3.75
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. https://app.cochat.ai/papers/10.18632/oncotarget.16348
The paper
Carrà, G., Panuzzo, C., Torti, D., Parvis, G., Crivellaro, S., Familiari, U., Volante, M., Morena, D., Lingua, M. F., Brancaccio, M., Guerrasio, A., Pandolfi, P. P., Saglio, G., Taulli, R., & Morotti, A. (2017). Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget. https://doi.org/10.18632/oncotarget.16348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.